Purpose: To determine the effects of short-and long-term use of autogenic drainage (AD) on pulmonary function and sputum recovery in people with cystic fibrosis (CF). Methods: The authors conducted a systematic review of randomized and quasi-randomized clinical trials in which participants were people with CF who use AD as their sole airway clearance technique. Results: Searches in 4 databases and secondary sources using 5 key terms yielded 735 articles, of which 58 contained the terms autogenic drainage and cystic fibrosis. Ultimately, 4 studies, 2 of which were long term, were included. All measured forced expiratory volume in 1 second (FEV 1 ) and found no change. The long-term studies were underpowered to detect change in FEV 1 ; however, the short-term studies found a clinically significant sputum yield (b4 g). Conclusion: AD has been shown to produce clinically significant sputum yields in a limited number of investigations. The effect of AD on the function of the pulmonary system remains uncertain, and questions have emerged regarding the appropriateness of FEV 1 as a valid measure of airway clearance from peripheral lung regions. Further consideration should be given to the use of FEV 1 as a primary measure of the effect of AD.
complete airway clearance daily to mitigate the effects of mucus retention in the lungs. [5] [6] [7] Autogenic drainage (AD), an airway clearance technique (ACT) recognized by the International Physiotherapy Group for CF, 8 was developed by Jean Chevaillier in 1967, 9-11 based on emerging theories and models of airflow in the lungs. [9] [10] [11] [12] [13] Performing AD involves taking tidal volume breaths, with inspiratory pauses, using controlled inspiratory and expiratory effort, over the vital capacity of the lungs. The cycle starts in the expiratory reserve volume and moves through functional residual capacity into the inspiratory reserve volume in three defined stages. This technique has been shown to create sustained airflow that is higher than usual in the airways of the lungs. 11, 13, 14 The increased airflow at low lung volumes is proposed to expedite the movement of mucus from the periphery of the lung (i.e., small airways) to the central airways and to improve ventilation, making it an appropriate treatment option given the evidence to date. 3, 11, 15 AD is a preferred ACT for many people with CF 16, 17 and is the third most used by Canadians with CF. 18 The population of people with CF is aging: 60% of Canadians with CF are adults, and the median age of survival, based on the Canadian CF data registry, is now 50.9 years compared with 40.9 years a decade ago. 19, 20 Standard CF care, including daily airway clearance, is acknowledged to be burdensome. 21 The continuous increase in life expectancy and increased focus on quality of life by health care professionals and patients alike make it imperative that we understand the effects of ACTs so they can be prescribed appropriately and used effectively. To date, no systematic review has examined the effects of AD in people with CF. The research question for our systematic review, therefore, was ''What are the effects of short-and long-term use of AD on pulmonary function and sputum recovery for people with CF?''
METHODS

Identification of studies
The protocol for our systematic review was registered with PROSPERO (registration no. CRD42014007118). We included randomized controlled trials (RCTs) or quasirandomized clinical trials investigating the effects of AD, as described by Chevaillier, 9, 11, 22 as the sole ACT for people with CF. We excluded studies if AD was combined with another ACT, if a modified method of AD was used, or if they investigated people who had received or were awaiting lung transplantation, because very poor lung function and increased respiratory rate make it unlikely that participants were able to properly perform AD.
Outcome measures
The outcome measures were pulmonary function (forced vital capacity [FVC] , forced expiratory volume in 1 s [FEV 1 ], and forced expiratory flow between 25% and 75% of forced vital capacity [FEF ]) and sputum recovery (dry or wet weight or volume of expectorated secretions). Pulmonary function values are used in CF research and clinical practice as primary outcome measures; [23] [24] [25] amount of expectorated sputum is a clinically relevant measure routinely used in clinical trials on airway clearance in CF. 6, 7 
Information sources
We searched five electronic databases-CINAHL , PEDro (1929 PEDro ( -2015 , the Cochrane Library , EMBASE (1974 EMBASE ( -2015 
Search strategy
The key search terms were autogenic drainage, cystic fibrosis, airway clearance, chest physiotherapy, and forced exhalation. No limits were placed on date of publication, type of study, or language; when possible, however, we imposed limits to include only studies with human participants. The results were narrowed using the Boolean operator NOT and the terms COPD (chronic obstructive pulmonary disease), primary ciliary dyskinesia, and ivacaftor. (See online supplement.)
Study selection
Using the key search terms, the primary author searched sources; a second author verified the process. We examined the title, abstract, keywords, and, if necessary, the body of the article using the terms cystic fibrosis AND autogenic drainage OR airway clearance OR chest physiotherapy. Any article on the subject of AD and CF was retained for further evaluation. After removing nonclinical trials, we independently reviewed the remaining articles, adhering to the guidelines set out in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 27 
Assessment of studies
Our assessment of bias was defined and informed by the Consolidated Standards of Reporting Trials (CONSORT) extension for non-pharmacologic treatments 28 and the Cochrane Collaboration Assessment of Risk of Bias of Included Studies Guideline; 29, 30 we used the PEDro scale 31, 32 to assess the quality of the methods. We independently reviewed the eligible articles, then met to discuss our findings and interpret the results using these tools. Inclusion was determined via consensus.
Data were extracted from each eligible study by the primary author and verified by a second author. An abbreviated version of the Cochrane Collaboration data extraction form for intervention reviews of RCTs and non-RCTs guided this process. 30 If data were noted to have been collected but were not reported, we contacted the corresponding author to request the information.
RESULTS
We retrieved a total of 735 unduplicated articles (see Figure 1 ). Of these, 58 met the preliminary selection criteria; 49 were then excluded because they were not RCTs (33), used AD in combination with another treatment (4), contained umbrella terms that did not include AD (5), used modified AD (breathing at self-selected lung volumes; 22 3), or were old abstracts and data of interest were unobtainable (4). Of the 49 excluded studies, 28 were review articles. A total of 9 publications, including one abstract, were reviewed; 5 of these were excluded because they investigated the German method of AD-''modified AD'' 22 (2) 33,34 -or because there was insufficient data to compare effects (3). [35] [36] [37] Two of these studies appeared very promising, 36,37 but the authors did not respond to our request to share their data.
Characteristics of studies
Four publications 6, 16, 38, 39 were ultimately included in our systematic review (see Table 1 ). There were 54 participants in total, aged 9-42 years, with an average FEV 1 of 59% predicted (range 45%-74%). The studies were published between 1992 and 2010; the most recent examined long-term AD use, whereas the older studies investigated single treatment sessions. The studies compared the effects of AD with at least one commonly used ACT. We found heterogeneity across studies with respect to how the AD technique was taught and assessed, as well as in treatment duration. None of the studies used an objective method to assess participants' AD technique or their adherence to treatment.
Critical Analysis
For risk-of-bias assessments, see the online supplement. Studies varied from having a low risk of bias 16 to an unclear risk of bias when the methods were not described in sufficient detail to allow categorization. 38, 39 One study had a moderate risk of bias resulting from incomplete data reporting, 6 because the authors reported collecting data at baseline and at 6 and 12 months, but the 6-month data were not included in the article. The quality of each study was good, ranging from 6 to 8 on the PEDro scale (Table 2) . 31, 32, 40 Effect of intervention All studies compared AD with different ACTs, but none found between-group differences in FEV 1 . To further evaluate the effects of AD on the outcomes of interest for this review, we isolated data specific to AD from each larger comparative study and created four data subsets of outcome measures for AD alone. These subsets presented pretest and posttest results with no control group 41 and were used to inform the results of this systematic review (see Table 1 ). Because the number of participants in each study who were using AD was low (10) (11) (12) (13) (14) (15) (16) (17) and the methodologies varied, meta-analysis was not possible.
The only outcome common to all four studies was FEV 1 , which did not change significantly after AD. McIlwaine and colleagues 16 found a predicted mean change in FEV 1 of less than 1% after 1 year of AD in adolescents, and Pryor and colleagues 6 found a non-significant change in mean FEV 1 of À0.04 L over 12 months in an adult AD group . The authors of the long-term studies reported inadequate power to detect a change in FEV 1 because of a large number of participant withdrawals. 6, 16 The shortterm studies also found non-significant differences in mean FEV 1 percent predicted before and after AD in people who were not having an exacerbation. 38,39 These short-term studies did not discuss power calculation and sample size, but all had small participant numbers, which suggests they may have been underpowered. FVC was reported in three studies. 16, 38, 39 Giles and colleagues 39 and McIlwaine and colleagues 16 reported a non-significant change of 2% or less after AD over the short and long term, respectively, and Pfleger and colleagues 38 reported significant improvement in mean FVC (5% predicted) after a single AD session. McIlwaine and colleagues, the only group to report FEF 25-75% , found a non-significant mean change of À1.91% over 1 year. 16 Short-term studies by Pfleger and colleagues 38 and Giles and colleagues 39 found a clinically significant yield of sputum (b4 g/session wet weight). 37 This minimal clinically important difference was based on the work of Osman and colleagues, 37 who assessed sputum expectoration in a single airway clearance session in people with CF. Participants in Pfleger and colleagues' 38 study, whose baseline sputum production was >20 mL per day, expectorated an average of 36 (SD 25) g over 80 minutes, whereas Giles and colleagues 39 reported that participants expectorated an average of 14 (SD 3) g over 60 minutes. 
DISCUSSION
The clinical trials included in our review demonstrate that AD is an ACT that generates clinically significant sputum yields, but they do not show significant improvement in FEV 1 in people with CF using AD over a short-or long-term period. The short-term studies measured sputum yield, which is the direct outcome of airway clearance, but the long-term studies omitted the challenging task of collecting and measuring the amount of sputum that participants cleared. All studies used FEV 1 as their primary outcome measure, making two inherent assumptions: first, that FEV 1 is sensitive to the removal of mucus from the lungs and therefore reflects the effectiveness of AD as an ACT, and, second, that 16 Pryor et al. 6 Giles et al. 39 Pfleger et al. 38 Random FEV 1 can improve, or at least be maintained, in people who complete airway clearance and follow the usual clinical course of CF. Currently, however, people with CF experience an average annual decline in FEV 1 of 2% predicted. 4 The short-term studies we reviewed showed that AD cleared a clinically significant amount of sputum in a single treatment session. Pfleger and colleagues 38 chose participants who produced copious amounts of secretions and found an improvement in their FVC. In contrast, participants in the study by Giles and colleagues, 39 who typically produced smaller amounts of sputum that were collected over a shorter time period, did not show an associated change in FVC after treatment. Sputum yield is considered a clinically relevant outcome measure, but its validity has repeatedly been challenged. 6, 7, 42, 43 Wet weight measurements of sputum may be contaminated by saliva or diminished because the person swallows mucus instead of expectorating it. 43 In addition, duration of the collection period can affect the sample amount. 43 The relationship between sputum clearance and pulmonary function remains unclear, 7 but the significant improvement in FVC after clearance of sputum using AD should not be ignored. An increase in FVC represents an increase in the volume of air that can be exhaled from the lungs. 44, 45 This air is exhaled from the larger, central airways as well as the smaller, peripheral airways, because the manoeuvre is aimed at exhaling one's vital capacity. 13, 14 CF disease slowly progresses in the peripheral airways, 3 producing a concentration of thick mucus. AD is proposed to remove this mucus and augment airflow in these small airways, which could account for the short-term improvement in FVC. [13] [14] [15] 38 The lack of improvement in FVC over the long term in the study by McIlwaine and colleagues 16 may reflect the multifactorial nature of CF disease progression, and FVC may therefore only be relevant for short-term evaluation of airway clearance.
The short-term studies found no significant effect of AD on FEV 1. In contrast to FVC, FEV 1 measures airflow in the large airways. 3, 46 Because of the brief nature of the FEV 1 manoeuvre, air is exhaled primarily from the proximal airways, because the lungs empty sequentially from the central to peripheral airways. Therefore, it is not surprising that FEV 1 did not change after AD in a group of people in a non-exacerbation state, because secretions are not concentrated in the large airways where they can obstruct airflow and diminish FEV 1 . The long-term studies investigated improvement of FEV 1 but did not find significant changes. Typically, the clinical course of CF results in an average annual decline in FEV 1 of 2% predicted. 4 It is interesting that neither study reported this decline in FEV 1 . Therefore, it is possible that AD may help preserve lung function over the course of the disease, in keeping with current goals of CF disease management. 47 However, in the absence of a controlled clinical study that is adequately powered, we cannot draw a definitive conclusion about the influence of AD on the preservation of FEV 1 .
FEV 1 remains the gold standard for measurement of CF disease progression, 24,48 but its status has been challenged in recent years by new evidence that pathological pulmonary changes occur in the peripheral airways while FEV 1 remains constant. 3, 49, 50 Over the longterm clinical course of CF, FEV 1 is considered a measure of irreversible damage to the large airways 3 and, once it is below 30% predicted, a significant predictor of mortality. 51 Improved survival and lack of deterioration in FEV 1 over time 4,48,52-54 make reliance on FEV 1 as a primary outcome measure in clinical practice and research challenging. 55 Clinically, FEV 1 represents the influence of multiple treatments on various components of CF disease, and therefore it cannot measure the specific influence of a particular intervention, such as airway clearance, over time. 25, [55] [56] [57] Clinical trials have struggled to generate sufficient power to detect a significant change in FEV 1 . 55, 56 Investigators should consider other measures and distinguish between assessing the effects of interventions and assessing CF disease progression when using such measures. In the meantime, perhaps researchers and clinicians should re-evaluate how they view FVC when assessing single-treatment interventions.
The AD interventions in the studies we reviewed were of varied duration, and AD skill and adherence were not assessed. Results were limited by small participant numbers, a lack of power to detect a change in FEV 1 (the primary outcome measure), and an unclear risk of bias in two of the four studies. Use of control groups, such as retrospective data from patients who were nonadherent to airway clearance, would have helped clarify the lack of change in FEV 1 because such patients might have shown comparatively significant declines. Finally, FEV 1 appears non-specific to the proposed effects of AD.
CONCLUSION
AD has been shown to produce clinically significant sputum yields, albeit in a small number of studies. The effect of AD on the function of the pulmonary system remains uncertain. Long-term studies did not demonstrate change in FEV 1 , although these studies were all underpowered and therefore firm conclusions could not be drawn. The results do, however, contribute to current debate on the appropriateness of FEV 1 as a primary outcome measure for the effectiveness of AD, and of other ACTs, in CF treatment. Future investigations should consider innovative designs and appropriate measures when evaluating the effectiveness of physiotherapy for people with CF.
KEY MESSAGES What is already known on this topic
Daily airway clearance is a standard of care for people with cystic fibrosis (CF). Autogenic drainage (AD) is the third most used airway clearance technique for Canadians with CF. Preliminary investigations suggest that AD can alter airflow and improve ventilation; however, the effects of AD, both short term and long term, have not been reviewed systematically.
What this study adds
AD has been shown to produce clinically significant sputum yields. The effect of AD on the function of the pulmonary system remains uncertain. The use of FEV 1 as a primary outcome measure of the direct effects of AD should be further deliberated. FVC may have clinical value in the assessment of an AD session, but more specific and sensitive measures are needed to validate longand short-term AD effects.
